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Background.  —  The  incidence  of  heart  failure  (HF)  is  stable  in  industrialized  countries,  but  its
prevalence  continues  to  increase,  especially  due  to  the  ageing  of  the  population,  and  mortality
remains high.
Objective.  —  To  estimate  the  incidence  in  France  and  describe  the  management  and  short-term
outcome  of  patients  hospitalized  for  HF  for  the  ﬁrst  time.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; AD, associated diagnosis; ALD, affections de longue durée; ARB,
ngiotensin II receptor blocker; BNP, brain natriuretic peptide; HF, heart failure; ICD 10, International Classiﬁcation of Diseases; PD, principal
iagnosis; RR, relative risk; SLM, local mutualist sections; SNIIRAM, Système National d’Information Inter-Régimes de l’Assurance Maladie.
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Method.  —  The  study  population  comprised  French  national  health  insurance  general  scheme
beneﬁciaries  (77%  of  the  French  population)  hospitalized  in  2009  with  a  principal  diagnosis
of HF  after  exclusion  of  those  hospitalized  for  HF  between  2006  and  2008  or  with  a  chronic
disease status  for  HF.  Data  were  collected  from  the  national  health  insurance  information  system
(SNIIRAM).
Results. —  A  total  of  69,958  patients  (mean  age  78  years;  48%  men)  were  included.  The  incidence
of ﬁrst  hospitalization  for  HF  was  0.14%  (≥  55  years,  0.5%;  ≥  90  years,  3.1%).  Compared  with  con-
trols without  HF,  patients  more  frequently  presented  cardiovascular  or  other  co-morbidities.
The hospital  mortality  rate  was  6.4%  and  the  mortality  rate  during  the  30  days  after  discharge
was 4.4%  (3.4%  without  readmission).  Among  30-day  survivors,  all-cause  and  HF  30-day  read-
mission rates  were  18%  (<  70  years,  22%;  ≥  90  years,  13%)  and  5%,  respectively.  Reimbursements
among  30-day  survivors  comprised  at  least  a  beta-blocker  in  54%  of  cases,  diuretics  in  85%,
angiotensin-converting  enzyme  inhibitors  (ACEIs)  or  angiotensin  receptor  blockers  (ARBs)  in
67%, a  diuretic  and  ACEI/ARB  combination  in  23%  and  a  beta-blocker,  ACEI/ARB  and  diuretic
combination  in  37%.
Conclusion.  —  Patients  admitted  for  HF  presented  high  rates  of  co-morbidity,  readmission  and
death at  30  days,  and  there  remains  room  for  improvement  in  their  drug  treatments;  these  ﬁnd-
ings indicate  the  need  for  improvement  in  return-home  and  therapeutic  education  programmes.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’incidence  de  l’insufﬁsance  cardiaque  (IC)  est  stable  dans  les  pays  industrialisés
mais sa  prévalence  continue  d’augmenter,  en  partie  face  au  vieillissement  de  la  population,  et
la mortalité  reste  élevée.
Objectif.  — Cette  étude  a  pour  but  d’estimer  l’incidence  et  de  décrire  la  prise  en  charge  et  le
devenir à  court  terme  des  patients  hospitalisés  une  première  fois  pour  IC  en  France.
Méthode.  — Parmi  les  bénéﬁciaires  du  régime  général  de  l’Assurance  maladie  (77  %  de  la  pop-
ulation franc¸aise)  hospitalisés  en  2009  avec  un  diagnostic  principal  d’IC,  ont  été  exclus  ceux
hospitalisés  pour  IC  entre  2006  et  2008  ou  avec  une  affection  de  longue  durée  pour  IC  et  les
informations  recueillies  à  partir  du  système  d’information  de  l’Assurance  maladie  (SNIIRAM).
Résultats.  — Au  total,  69  958  patients  ont  été  inclus  (âge  moyen  78  ans,  48  %  d’hommes).
L’incidence  était  de  0,14  %  (≥  55  ans  :  0,5  %  ;  ≥  90  ans  :  3,1  %).  Par  rapport  à  des  témoins  assurés
sans IC  et  avec  prise  en  compte  de  l’âge,  les  malades  présentaient  plus  souvent  des  comorbidités
cardiovasculaires  ou  non.  Un  décès  était  retrouvé  chez  6,4  %  des  patients  lors  de  l’hospitalisation
et 4,4  %  d’entre  eux  30  jours  après  leur  sortie  (3,4  %  sans  réhospitalisation).  Pour  les  survivants
à 30  jours,  5  %  ont  été  réhospitalisés  avec  un  diagnostic  principal  d’IC  et  18  %  tous  diagnos-
tics inclus  (22  %  pour  les  <  70  ans  et  13  %  pour  les  ≥  90  ans).  Parmi  les  survivants  à  un  mois,  54  %
avaient au  moins  un  remboursement  d’un  médicament  de  la  classe  des  bêtabloquants,  85  %  d’un
diurétique,  67  %  d’un  inhibiteur  de  l’enzyme  de  conversion  (IEC)  ou  d’un  antagoniste  des  récep-
teurs de  l’angiotensine  2  (ARA2)  et  23  %  avaient  une  association  bêtabloquant  et  IEC/ARA2  et
37 %  une  telle  association  avec  un  diurétique.
Conclusion.  —  Les  patients  avec  une  première  hospitalisation  pour  IC  ont  une  fréquence  élevée
de comorbidités,  de  réhospitalisations  et  de  décès  à  30  jours  et  l’utilisation  des  médicaments
indiqués  pourrait  être  améliorée.  Cela  est  en  faveur  d’une  réﬂexion  sur  la  promotion  de  pro-
grammes de  retour  à  domicile  et  d’éducation  thérapeutique.
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Background
Heart  failure  (HF)  is  a  common  and  disabling  syndrome.  The
incidence  of  HF  is  stable  in  industrialized  countries,  but
its  prevalence  continues  to  increase,  especially  due  to  the
ageing  of  the  population.  The  incidence  of  HF  is  currently
estimated  to  be  between  5  and  10  per  1000  subject-years,
depending  on  the  cohorts  studied;  the  prevalence  is  esti-
mated  to  be  between  1%  and  3%  in  industrialized  countries
[1,2].  The  incidence  and  prevalence  of  HF  markedly  increase
with  age.  For  example,  the  Framingham  study  reported
d
e
ps  droits  réservés.
 prevalence  of  clinical  HF  of  0.8%  in  subjects  aged
0—59  years  and  of  9.1%  in  those  aged  80—89  years  in  1993
3]. The  mortality  of  patients  with  HF  has  decreased  over
he  past  two  decades,  but  remains  high,  with  a  standardized
ortality  rate  in  Europe  of  32.6/100,000  in  2008  [4].
HF  accounts  for  1—2%  of  all  healthcare  expenditure  and
epresents  the  leading  cause  of  hospitalization  after  the
ge  of  65  years  in  industrialized  countries  [2,5]. This  syn-
rome  is  characterized  by  a  high  rate  of  hospitalizations,
specially  for  acute  decompensation.  In  France,  among  all
atients  hospitalized  for  HF  in  2008,  7.5%  died  during  their
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ospitalization  and  21%  were  readmitted  for  HF  during  the
ame  year  [6].  A  high  readmission  rate  is  observed  during
he  30  days  after  discharge;  for  example,  5.6%  of  veter-
ns  in  the  USA  were  readmitted  for  a  diagnosis  of  HF  and
2%  for  all  diagnoses  combined  between  2002  and  2006
7].  Sixty-one  percent  of  patients  hospitalized  for  HF  in  the
SA  presented  at  least  one  factor  of  decompensation  [8].
ased  on  these  ﬁndings,  disease  management  programmes
efore  and  after  hospital  discharge,  comprising  health-
are  organization,  patient  education,  training  of  healthcare
rofessionals  and/or  home  surveillance,  have  been  demon-
trated  to  be  effective  in  many  trials  and  have  consequently
een  included  in  guidelines  [9—11].
This  study  was  designed  to  estimate  the  incidence  and
escribe  the  clinical  characteristics,  treatment  and  30-day
utcome  of  patients  presenting  a  ﬁrst  hospitalization  for  HF
n  France  among  national  health  insurance  general  scheme
eneﬁciaries,  representing  77%  of  the  French  population.
ethods
nformation system and population
n  France,  the  Système  National  d’Information  Inter-
égimes  de  l’Assurance  Maladie  (SNIIRAM;  French  national
nter-regime  health  insurance  information  system)  com-
rises  an  individual  and  anonymous  database  concerning  the
eneﬁciaries  of  the  various  schemes.  The  database  compre-
ensively  records  all  outpatient  prescriptions,  services  and
rocedures  performed  and  reimbursed,  together  with  their
ates,  with  historical  data  limited  to  a  period  of  3  years
lus  the  current  year.  Medications  are  identiﬁed  according
o  Anatomical  Therapeutic  Classiﬁcation  Code,  laboratory
ests  are  identiﬁed  from  the  French  National  Laboratory  Test
oding  Table  and  the  procedures  performed  on  an  outpa-
ient  basis  or  in  private  institutions  are  identiﬁed  according
o  the  Classiﬁcation  Commune  des  Actes  Médicaux  (French
edical  classiﬁcation  for  clinical  procedures).  The  SNIIRAM
oes  not  contain  any  clinical  information  concerning  results
elated  to  prescriptions  or  examinations.  Nevertheless,  it
ndicates  the  presence  of  any  ‘affections  de  longue  durée’
ALD;  chronic  diseases),  such  as  cardiovascular  diseases,
hich  are  eligible  for  100%  reimbursement  of  healthcare
xpenditure  after  application  by  the  attending  physician  and
pproval  by  the  national  health  insurance  consultant  physi-
ian.  These  chronic  diseases  are  coded  according  to  the
nternational  Classiﬁcation  of  Diseases  (ICD  10).  An  anony-
ous  unique  identiﬁcation  number  for  each  subject  links
his  information  to  data  collected  by  the  Programme  de
édicalisation  des  Systèmes  d’Information  (national  hospi-
al  discharge  database)  in  healthcare  institutions.  During  the
atient’s  stay,  principal  diagnoses  (PDs),  related  diagnoses
nd  associated  diagnoses  (ADs)  are  coded  according  to  ICD
0  and  the  procedures  performed  are  coded  according  to
he  Classiﬁcation  Commune  des  Actes  Médicaux.  In  2009,
he  national  health  insurance  general  scheme  covered  about
7%  of  the  64  million  inhabitants  in  France,  excluding  the
3%  covered  by  local  mutualist  sections  (SLM:  students,  civil
ervants,  etc.).  One  of  the  reasons  for  limiting  the  study
o  this  population  was  the  availability  of  vital  status  and
ate  of  death  from  the  National  Institute  for  Statistics  and
E
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conomic  Studies  (INSEE).  The  rest  of  the  French  popula-
ion  is  covered  by  the  Mutualité  Sociale  Agricole,  the  Régime
ocial  des  Indépendants  and  other  speciﬁc  health  insurance
chemes.
This  study  was  based  on  the  subpopulation  covered  by
he  national  health  insurance  general  scheme  because,  at
he  present  time,  the  patient’s  survival  status  is  not  pre-
isely  indicated  in  the  SNIIRAM  for  the  other  health  insurance
chemes.  The  ﬁrst  hospitalization  in  2009  with  a  PD  of  HF
ICD  code  I50  heart  failure)  was  selected  to  identify  eligible
atients.  Hospitalizations  with  the  following  PDs  were  not
ncluded:  I11.0  hypertensive  heart  disease;  I13.0  hyperten-
ive  heart  and  renal  disease  with  (congestive)  heart  failure;
13.2  hypertensive  heart  and  renal  disease  with  (congestive)
eart  failure  and  renal  failure;  I13.9  hypertensive  heart  and
enal  disease,  unspeciﬁed;  K76.1  chronic  passive  congestion
f  liver;  and  J81  pulmonary  oedema.  Eligible  patients  hos-
italized  with  a  PD  of  HF  between  2006  and  2008,  an  AD  of
F  in  2008  and/or  ALD  chronic  disease  status  for  HF  before
he  index  hospitalization  were  then  excluded.
eﬁnitions
he  search  for  co-morbidities  before  the  ﬁrst  hospitalization
or  HF  took  into  account  the  presence  of  speciﬁc  chronic
iseases  and  the  presence,  during  the  previous  year,  of  at
east  one  hospitalization  with  a  PD  for  hypertensive  disease,
oronary  heart  disease  or  cardiomyopathy.  ‘Tumour’  chronic
iseases  were  subdivided  into  tumours  of  haematopoietic
issues  (ICD  codes  C81  to  C96)  and  breast  tumours  (C50).
Data  reported  for  the  index  hospitalization  for  HF
ncluded  the  number  and  types  of  medical  units  coded  in  the
rogramme  de  Médicalisation  des  Systèmes  d’Information
intensive  care,  cardiac  intensive  care,  palliative  care,
tc.).  Readmissions  were  taken  into  account  whatever  the
eason  for  admission,  when  they  occurred  between  7  and
0  days  after  discharge,  in  order  to  eliminate  early  trans-
ers.  Readmissions  were  classiﬁed  according  to  the  presence
f  a  PD  or  AD  code  for  HF.
Drug  treatments  were  identiﬁed  by  the  presence  of  at
east  three  reimbursements  during  the  6  months  preceding
he  index  hospitalization  and  by  a  single  reimbursement
uring  the  30  days  following  discharge.  Beta-blockers  with
arketing  authorization  for  the  treatment  of  HF  were
rouped  under  the  term  ‘speciﬁc’.  Potassium-sparing  diuret-
cs  combined  with  another  diuretic  in  ﬁxed-combination
edicinal  products  were  distinguished.  Patients  with  no
edicinal  product  reimbursement,  all  classes  combined,
uring  the  6  months  preceding  and/or  the  30  days  follow-
ng  hospitalization  (mainly  patients  living  in  an  institution
irectly  dispensing  medicinal  products)  were  excluded  from
he  comparative  study  of  treatments  before  and  after  hos-
italization.
Echocardiographs  were  identiﬁed  by  the  presence  of  a
peciﬁc  code,  whether  they  were  performed  in  hospital  or
n  an  outpatient  basis.  Reimbursements  for  cardiology  hos-
ital  outpatient  and  ofﬁce  visits  were  taken  into  account.
chocardiography  was  not  systematically  coded  during  a  car-
iology  visit,  as  the  levels  of  reimbursement  may  be  similar
or  a  visit  with  or  without  echocardiography.  To  compen-
ate  for  this  missing  coding,  a  variable  was  constructed  by
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aFigure 1. Incidence rate of a ﬁrst hospitalization for heart failure
in 2009 (n = 69,958).
combining  the  existence  of  at  least  one  visit  to  the  cardiol-
ogist  or  echocardiography.
Laboratory  assays  such  as  brain  natriuretic  peptide  (BNP)
could  not  be  identiﬁed  when  they  were  performed  in  a  public
hospital,  as  they  are  not  reimbursed  individually.
Statistical analysis
The  incidence  of  a  ﬁrst  hospitalization  for  HF  was  calculated
from  all  patients  selected  in  2009  divided  by  the  number  of
individuals  covered  by  the  national  health  insurance  general
scheme,  apart  from  SLM,  at  31  December  2009,  according  to
age  and  sex.  Regional  incidence  rates  were  standardized  for
age  and  sex  of  the  general  scheme  population.
The  mortality  rate  was  calculated  during  hospitalization,
during  the  30  days  after  admission  and  during  the  30  days
after  discharge.  Readmissions  were  expressed  as  patients
with  at  least  one  readmission  with  a  diagnosis  of  HF  (as  PD
and  PD  or  AD)  or  for  all  diagnoses  combined.
Patient  and  management  characteristics  were  studied
among  those  patients  still  alive  at  30  days  and  compared
with  those  of  all  patients  hospitalized.  The  frequencies  of
co-morbidities  and  the  consumption  of  certain  medicinal
products  were  compared  between  these  patients  and  the
other  subjects  covered  by  the  general  scheme.  A  frequency
ratio  (relative  risk  [RR])  was  calculated  according  to  age  for
the  two  groups,  with  a  95%  conﬁdence  interval.  This  ratio
was  also  standardized  for  age  and  sex  among  subjects  aged
≥  55  years.
Statistical  analyses  were  performed  with  SAS  Enterprise
Guide  software,  version  4.3  (SAS  Institute  Inc.,  Cary,  NC,
USA).
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0e and sex among subjects covered by the general scheme in France
esults
n  2009,  for  152,601  patients,  200,412  hospital  stays  with  a
rincipal  diagnosis  of  HF  were  recorded  for  all  of  France.
mong  them,  98,124  patients  and  130,333  hospitalizations
oncerned  people  covered  by  the  general  scheme,  excluding
LM.  After  exclusion  of  patients  previously  hospitalized  for
F  between  2006  and  2008  (n  =  24,047)  and  the  remaining
atients  with  an  ALD  chronic  disease  status  before  hospi-
alization  (n  =  4119),  a  total  of  69,958  patients  with  a  ﬁrst
ospitalization  with  a  PD  of  HF  in  2009  were  included  in  the
tudy.  Forty-eight  percent  of  these  patients  were  men;  the
ean  age  was  78  years.  The  mean  length  of  stay  was  9  days
nd  the  median  length  of  stay  was  8  days.  Patients  with  a
rst  hospitalization  in  2009  totalled  1.2%  of  all  patients  hos-
italized  in  2009  (1.3%  for  men  and  1.2%  for  women),  2.6%
f  those  aged  70—79  years,  6.2%  of  those  aged  80—89  years
nd  10.9%  of  those  aged  ≥  90  years.
ncidence of ﬁrst hospitalization for heart
ailure
he  incidence  of  a  ﬁrst  hospitalization  for  HF  was  0.14%
or  the  whole  population  (all  ages  combined)  and  0.5%  for
atients  aged  ≥  55  years  (Fig.  1).  This  incidence  increased
onsiderably  after  the  age  of  70  years  and  was  >  3%  after  the
ge  of  90  years.  Men  presented  a  slightly  higher  incidence
han  women  for  all  age  groups  considered  (0.55%  vs.  0.48%
or  patients  aged  ≥  55  years).  The  age-  and  sex-standardized
ncidence  according  to  region  ranged  between  0.11%  and
.18%  (Fig.  2);  it  was  higher  in  northern  and  north-western
574  
Figure 2. Age- and sex-standardized regional incidence rates of
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2 ﬁrst hospitalization for heart failure per 100 general scheme ben-
ﬁciaries in France in 2009 (n = 69,958).
egions,  Corsica  and  Réunion,  and  lower  in  south-eastern
nd  Île-de-France  regions.
utcome of hospitalized patients: death and
eadmissions
he  hospital  mortality  rate  was  6.4%  (Table  1).  After  stan-
ardization  for  age,  this  rate  was  slightly  higher  in  men  than
n  women  (6.7%  vs.  5.9%).  The  hospital  mortality  rate  was
.0%  in  patients  aged  <  55  years  and  12.8%  in  patients  aged
 90  years.  The  mortality  rate  during  the  30  days  after  dis-
harge  was  4.4%,  without  readmission  for  three-quarters  of
ases.
For  patients  surviving  30  days  after  discharge,  at  least
ne  readmission  (all  diagnoses  combined)  was  reported
ithin  30  days  for  18%  of  patients,  with  HF  as  the  PD  or  AD
n  9%  of  patients  and  HF  as  the  PD  in  5%  of  patients.  Among
atients  readmitted,  more  than  half  had  a  cardiovascular
isease  as  a  PD,  12%  had  a  factor  inﬂuencing  health  status
nd  contact  with  health  services,  7%  had  a  pulmonary  dis-
ase  and  4%  had  cancer.  These  readmission  rates  were  higher
mong  the  youngest  patients,  especially  for  all-cause  read-
issions  (21.7%  for  patients  aged  <  69  years  and  12.7%  for
atients  aged  ≥  90  years).
re- and post-hospitalization management of
atients surviving 30 days after discharge
uring  the  year  preceding  hospitalization,  almost  46%  of
atients  had  undergone  at  least  one  echocardiography  or
ad  consulted  a  cardiologist,  and  at  least  one  BNP  assay  had
een  reimbursed  for  40%  of  them  (Table  2).  Eighteen  percent
f  these  patients  were  hospitalized  in  a  private  hospital,  21%
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n  a university  hospital  (36%  of  patients  aged  <  55  years)  and
1%  in  a  public  hospital.  More  than  one  quarter  of  patients
ere  admitted  to  an  intensive  care  unit  or  intermediate  care
nit  (almost  40%  of  patients  aged  <  55  years).  At  the  time
f  discharge,  79%  of  patients  returned  home  and  21%  were
ransferred  to  another  unit,  including  a  rehabilitation  unit
n  one  half  of  cases.  Thirty  days  after  discharge  from  hospi-
al,  29%  of  patients  had  had  at  least  one  echocardiography
r  had  attended  a  cardiology  follow-up  visit;  16%  had  had  at
east  one  BNP  assay.  No  medicinal  product  reimbursement
all  classes  combined)  was  observed  for  4.9%  of  patients
uring  the  year  preceding  hospitalization  (5.2%  for  patients
ged  ≥  90  years)  and  for  12.7%  of  patients  during  the  30  days
fter  discharge  (19.7%  for  patients  aged  ≥  90  years).
o-morbidities of  patients surviving 30 days
fter discharge
hese  patients  had  a  chronic  disease  recognized  as  an  ALD  in
1%  of  cases  (Table  3).  Over  the  age  of  55  years,  the  preva-
ence  of  chronic  diseases  was  signiﬁcantly  higher  for  each
orm  of  cardiac  disease,  such  as  hypertension  (RR  1.5),  coro-
ary  heart  disease  (RR  1.7),  arrhythmias  (RR  2.0),  valvular
eart  disease  (RR  3.1),  but  also  for  other  co-morbidities  such
s  diabetes  (RR  1.9),  chronic  respiratory  failure  (RR  1.6),
hronic  kidney  disease  (RR  2.2),  chronic  liver  disease  (RR
.6)  and  psychiatric  diseases  (RR  1.2).  Only  Alzheimer’s  dis-
ase  was  less  common  among  these  patients  (RR  0.6).  These
atients  also  more  frequently  presented  ALD  status  for  a
umour  of  haematopoietic  tissue  (RR  1.3)  or  breast  cancer
n  women  (RR  1.1).  The  RR  values  for  these  tumours  and  psy-
hiatric  illness  and  reimbursements  for  antipsychotic  drugs
ere  inversely  correlated  with  patient  age.
rug treatments
 total  of  53,168  patients  (85%  of  survivors  at  30  days)
eceiving  at  least  one  drug  reimbursed  1  year  before  and
0  days  after  their  ﬁrst  hospitalization  for  heart  failure
ere  selected  for  a  comparison  of  the  time-course  of
eimbursement  of  the  main  drugs  (Table  4).  The  use  of  beta-
lockers  increased  after  hospitalization  from  40%  to  54%;
he  use  of  speciﬁc  beta-blockers  increased  from  14%  to  31%.
lthough  60%  of  patients  were  being  reimbursed  at  least  a
iuretic  before  their  hospitalization,  this  frequency  was  85%
uring  the  month  following  hospitalization  (loop  diuretic,
ncrease  from  46%  to  81%;  potassium-sparing  diuretic,  10%  to
7%;  ﬁxed  combination  of  a  potassium-sparing  diuretic  and
nother  diuretic,  9%  to  16%).  Prescription  of  angiotensin-
onverting  enzyme  inhibitors  (ACEIs)  increased  from  32%
o  47%,  while  prescription  of  angiotensin  II  receptor  block-
rs  (ARBs)  decreased  from  26%  to  21%  and  prescription
f  either  an  ACEI  or  an  ARB  increased  from  56%  to  67%.
rescription  of  a  beta-blocker,  diuretic  and  ACEI/ARB  com-
ination  increased  from  21%  to  37%  and  prescription  of  a
iuretic  and  ACEI/ARB  combination  increased  from  21%  to
3%.  These  frequencies  and  their  variations  after  hospital-
zation  were  higher  among  the  youngest  patients.  Younger
atients  more  frequently  beneﬁted  from  an  implantable
ardioverter-deﬁbrillator  either  during  initial  hospitaliza-
ion  or  within  the  following  month  (3%).
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Table  1 Mortality  rates  among  69,958  patients  with  a  ﬁrst  hospitalization  for  heart  failure  in  2009,  during  hospitalization  and  30  days  after  discharge,  according  to
the  presence  of  at  least  one  readmission  and,  for  the  62,417  survivors  at  30  days,  at  least  one  readmission  between  7 and  30  days  after  discharge,  by  age  and  sex.
<  55  years 55—69  years 70—79  years 80—89  years ≥ 90  years Womena Mena Total
First  hospitalization  (n) 4005  10,731  17,600  28,888  8734  33,408  36,550  69,958
Death  (%)
During  and  30  days  after  hospitalization 3.7 5.1 7.3 12.7 21.6 10.1 11.8 10.8
During  hospitalization 2.0 2.9 4.3 7.6 12.8 5.9 6.7 6.4
During  the  30  days  after  discharge 1.7 2.2 3.0  5.1  8.8  4.2  5.1  4.4
With  readmission  for  HF  as  PD 0.1 0.1 0.2  0.3  0.4  0.2  0.3  0.3
With  readmission  for  HF  as  PD  or  AD 0.1 0.3 0.4 0.7  0.7  0.5  0.6  0.5
With  readmission:  all  diagnoses 0.2 0.7 0.8  1.3  1.2  0.9  1.2  1.0
Without  readmission  1.4  1.5  2.2  3.8  7.6  3.2  3.9  3.4
Survivors  at  30  days  (n)  3858  10,184  16,309  25,225  6841  32,365  30,052  62,417
Readmission  (%)
With  HF  as  PD  5.0  5.6  5.2  5.1  4.5  4.8  5.4  5.1
With  HF  as  PD  or  AD  9.9  10.1  9.6  8.8  7.4  8.3  9.8  9.1
All  diagnoses  21.7  21.7  19.8  16.3  12.7  16.7  19.5  18.0
AD: associated diagnosis; HF: heart failure; PD: principal diagnosis.
a Adjustment for age.
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Table  2  Characteristics  history  and  management  of  62,417  patients  surviving  at  least  30  days  after  discharge  after  a  ﬁrst  hospitalization  for  heart  failure  in  2009,
by  age  and  sex,  compared  with  the  characteristics  of  all  patients  hospitalized  for  heart  failure.
Survivors  at  30  days  Hospitalized
<  55  years  55—69  years  70—79  years  80—89  years  ≥  90  years  Womena Mena Total
Number  of  patients  (n)  3858  10,184  16,309  25,225  6841  32,365  30,052  62,417  69,958
Mean  age  (years)  —  —  —  —  —  80.1  73.7  77.0  77.7
Men  (%)  65.4  67.7  56.4  41.4  24.3  —  —  49.4  47.8
One  year  before  hospitalization  (%)
At  least  one  reimbursement
Echocardiography  35.5  42.5  45.0  38.9  25.9  37.6  42.1  39.4  38.4
Cardiologist  visit  or  echocardiography  44.1  50.3  52.5  44.3  30.0  43.3  49.5  45.9  44.6
BNP  assay  27.1  36.7  42.7  42.5  38.3  38.5  42.5  40.2  40.0
Hospitalization  with  a  PD
Hypertensive  disease  1.1  1.0  0.9  1.0  0.9  1.2  0.7  1.0  1.0
Coronary  heart  disease  or  cardiomyopathy  11.0  10.3  8.8  5.9  2.7  5.9  8.7  7.4  7.2
Chronic  disease  (ALD)
No  chronic  disease  52.2  32.4  23.8  25.7  33.0  29.8  26.6  28.7  28.2
Severe  hypertension  4.5  12.2  16.5  18.8  19.6  17.9  14.0  16.3  16.4
Coronary  heart  disease  7.1  13.7  15.8  16.8  15.8  10.4  20.4  15.3  15.3
Serious  arrhythmias  1.2  2.8  5.1  6.1  5.0  5.2  4.7  4.9  4.8
Serious  valvular  heart  disease  3.3  4.0  4.0  3.7  2.8  4.3  3.5  3.7  3.7
Diabetes  10.5  25.7  26.9  17.7  8.9  20.6  19.8  20.0  19.8
Chronic  respiratory  failure  1.9  3.7  4.4  3.4  2.0  2.9  4.1  3.5  3.6
Serious  chronic  kidney  disease  2.9  2.0  1.5  0.9  0.7  1.3  1.5  1.3  1.3
Malignant  tumour  4.7  9.2  13.0  12.7  9.6  10.2  13.6  11.4  11.7
Haematopoietic  tissues  1.4  1.3  1.3  1.0  0.6  1.2  1.1  1.1  1.1
Breast  (women)  4.3  6.8  5.7  4.7  3.4  5.1  —  4.9  4.8
Alzheimer’s  disease  0.0  0.1  1.0  3.2  5.5  2.6  1.3  2.2  2.5
Parkinson’s  disease  0.0  0.3  0.8  1.0  1.2  0.8  0.8  0.8  0.9
Chronic  liver  disease  1.5  1.3  0.9  0.4  0.1  0.7  0.7  0.7  0.7
Psychiatric  illness  6.0  4.3  2.8  1.9  1.5  3.8  1.8  2.7  2.7
Antipsychotics  reimbursed  4.8  3.6  3.0  2.9  4.6  4.2  2.5  3.3  3.5
No  medicinal  product  reimbursed  12.5  7.5  3.7  3.5  5.2  4.5  4.8  4.9  5.0
Index  hospitalization  (%)
Hospital  category
Private  hospital  15.2  20.0  19.9  18.4  14.9  17.3  19.9  18.4  18.1
University  hospital  35.7  24.6  20.5  18.9  20.5  21.5  21.1  21.5  21.2
General  hospital  49.1  55.5  59.6  62.7  64.6  61.2  58.9  60.1  60.8
Medical  units  frequented
1  57.4  56.9  58.6  59.8  65.7  58.6  60.3  59.5  59.6
2  29.2  31.5  30.8  31.7  29.2  31.6  30.4  31.0  30.6
≥  3  13.5  11.6  10.6  8.4  5.1  9.8  9.4  9.5  9.8
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Table  2  (Continued)
Survivors  at  30  days Hospitalized
<  55  years 55—69  years 70—79  years 80—89  years ≥ 90  years Womena Mena Total
Stay  in
Intensive  care  unit 5.3  4.0  2.9  1.5  0.6  2.4  2.3  2.4 2.8
Cardiac  intensive  care  unit 27.9  26.8  21.5  16.8  9.1  18.8  20.5  19.5 19.5
Intermediate  care  unit 5.4  5.2  5.4  5.0  3.9  5.0  5.2  5.0 5.2
Palliative  care  unit 1.1  2.0  2.4  2.6  3.0  2.4  2.3  2.4 2.5
Length  of  stay  (nights)
<  2 15.8 10.2  7.2  6.4  8.4  7.9  7.9  8.0 9.1
2—5 33.3  30.7  25.9  21.9  21.9  23.1  26.9  25.1 24.9
6—10 29.1  34.2  36.9  36.6  34.7  36.0  35.5  35.6 34.3
11—15 12.5  14.4  16.7  19.5  19.3  18.4  16.5  17.5 17.2
≥  16  9.3  10.5  13.2  15.6  15.7  14.5  13.2  13.8  14.5
Mean  (days)  7.4  8.2  9.0  9.8  9.6  9.4  8.9  9.2  9.2
Mode  of  discharge
Home  79.0  82.0  81.9  77.1  73.6  77.6  81.0  78.9
Transfer  21.0  18.0  18.1  22.9  26.4  22.3  18.9  21.1
To  a  rehabilitation  unit  3.9  4.0  6.3  11.7  14.8  10.0  7.3  8.9
30  days  after  hospitalization  (%)
At  least  one  reimbursement
Echocardiography  15.1  14.5  12.4  9.4  6.1  10.7  11.6  11.0
Cardiology  visit  or  echocardiography  29.9  34.0  32.1  27.1  18.5  27.5  30.7  28.8
GP  visit  62.3  68.3  74.0  72.5  70.5  71.9  71.7  71.4
BNP  assay  12.8  15.6  16.5  16.7  15.6  15.5  17.0  16.1
Serum  creatinine  38.9  48.1  51.3  49.4  44.3  46.7  50.4  48.5
Potassium  22.6  27.2  29.0  29.7  27.6  28.8  28.2  28.5
No  medicinal  product  reimbursed  (%) 10.9  8.4  9.8  14.7  19.7  13.9  10.8  12.7
ALD: affections de longue durée; BNP: brain natriuretic peptide; PD: principal diagnosis.
a Adjustment for age.
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Table  3  Frequency  of  certain  chronic  diseases  (ALD)  among  general  scheme  beneﬁciaries  who  survived  30  days  after  a  ﬁrst  hospitalization  for  heart  failure  in  2009
over  the  frequency  among  other  beneﬁciaries  in  2009,  by  age  group.
<  40  years  40—54  years  55—69  years  70—79  years  80—89  years  ≥  90  years  Total  ≥  55  yearsa
(n  =  830) (n =  3028)  (n  =  10,184)  (n  =  16,309)  (n  =  25,525)  (n  =  6491)
No  chronic  disease  0.6  [0.6—0.7]  0.6  [0.5—0.6]  0.5  [0.4—0.5]  0.4  [0.4—0.5]  0.7  [0.6—0.7]  1.2  [1.2—1.3]  0.6  [0.6—0.6]
Hypertension  44.5  [25.9—76.3]  6.3  [5.4—7.3]  3.0  [2.9—3.2]  1.9  [1.8—1.9]  1.4  [1.4—1.5]  1.2  [1.1—1.2]  1.5  [1.5—1.6]
Coronary  heart  disease  87.7  [53.9—142.6]  10.5  [9.4—11.8]  4.3  [4.1—4.5]  2.4  [2.3—2.5]  1.8  [1.7—1.8]  1.3  [1.3—1.4]  1.7  [1.7—1.8]
Arrhythmias  108.7  [58.6—201.5]  15.2  [11.1—21.0]  5.4  [4.8—6.1]  2.9  [2.7—3.1]  1.8  [1.8—1.9]  1.4  [1.2—1.5]  2.0  [1.9—2.0]
Valvular  heart  disease  119.8  [76.7—187.0]  28.9  [24.0—34.7]  9.3  [8.5—10.3]  3.9  [3.7—4.3]  2.5  [2.3—2.6]  2.2  [1.9—2.5]  3.1  [2.9—3.2]
Diabetes  12.7  [8.9—18.2]  5.3  [4.8—5.8]  3.3  [3.2—3.4]  2.3  [2.2—2.3]  1.6  [1.6—1.7]  1.2  [1.1—1.3]  1.9  [1.9—2.0]
Chronic  respiratory  failure  4.3  [2.0—9.6]  5.8  [4.6—7.4]  3.5  [3.1—3.8]  2.1  [2.0—2.3]  1.3  [1.3—1.4]  0.9  [0.7—1.0]  1.6  [1.5—1.6]
Chronic  kidney  disease  41.2  [27.0—62.8]  19.2  [15.7—23.5]  7.4  [6.5—8.5]  3.4  [3.0—3.9]  1.5  [1.3—1.7]  1.0  [0.8—1.3]  2.2  [2.0—2.3]
Malignant  tumours  12.1  [8.5—17.4]  2.3  [2.0—2.7]  1.3  [1.3—1.4]  1.0  [1.0—1.1]  1.0  [0.9—1.0]  0.9  [0.8—1.0]  1.0  [0.9—1.0]
Haematopoietic  tissues  26.1  [15.8—43.0]  7.2  [5.3—9.8]  2.9  [2.5—3.4]  1.5  [1.3—1.7]  1.0  [0.9—1.1]  0.8  [0.6—1.1]  1.3  [1.2—1.4]
Breast  cancer  (women)  14.1  [6.1—43.1]  2.1  [2.6—4.4]  1.7  [1.5—1.9]  1.1  [1.0—1.2]  1.1  [1.0—1.2]  1.0  [0.9—1.2]  1.1  [1.1—1.2]
Alzheimer’s  disease  —  —  1.0  [0.7—1.6]  0.9  [0.8—1.0]  0.6  [0.6—0.7]  0.5  [0.5—0.5]  0.6  [0.6—0.6]
Parkinson’s  disease  —  —  1.3  [0.9—1.9]  1.0  [0.8—1.2]  0.7  [0.7—0.8]  0.8  [0.6—1.0]  0.9  [0.8—1.0]
Chronic  liver  disease  15.3  [8.0—29.4]  2.8  [2.1—3.8]  2.2  [1.8—2.6]  1.6  [1.4—1.9]  1.2  [1.0—1.5]  1.0  [0.5—2.1]  1.6  [1.5—1.8]
Psychiatric  illness  4.7  [3.4—6.3]  2.3  [2.0—2.6]  1.5  [1.4—1.6]  1.2  [1.1—1.4]  0.9  [0.8—1.0]  0.7  [0.6—0.8]  1.2  [1.1—1.2]
Reimbursement  of  antipsychotics  6.2  [4.5—8.4]  2.4  [2.1—2.8]  1.6  [1.4—1.8]  1.3  [1.2—1.5]  0.9  [0.9—1.0]  0.8  [0.7—0.9]  1.1  [1.0—1.1]
Data are presented as frequency ratio (i.e. relative risk) [95% conﬁdence interval]. ALD: affections de longue durée.
a Sex- and age-standardized.
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Table  4 Comparison  of  treatments  6  months  before  hospitalization  and  30  days  after  discharge  among  patients  surviving  at  least  30  days  after  a  ﬁrst  hospitalization
for  heart  failure  in  2009.
<  55  years  55—69  years  70—79  years  80—89  years  ≥  90  years  Womena Mena Total
Number  of  patients  (n) 3122  8810  14,444  21,317  5475  27,086  26,082  53,168
Mean  age  (years) —  —  —  —  —  79.8  74.0  77.0
Men  (%) 63.7 66.5  55.6  41.5  24.8  —  —  49.1
6  months  before  (%)
Beta-blockers  29.6  42.5  44.7  39.3  28.7  39.2  39.7  39.6
Speciﬁc  beta-blocker 14.6  15.5  16.0  13.8  10.5  12.1  16.4  14.4
ARB  11.1  23.9  29.2  27.3  20.6  28.3  22.9  25.6
ACEI  25.0  33.8  35.0  31.9  27.1  27.6  36.7  32.2
ACEI  or  ARB 34.9  55.1  61.9  57.9  46.9  54.3  57.7  56.0
Diuretics  (at  least  one) 31.8  50.8  61.9  65.5  62.6  60.6  59.4  59.8
Loop  diuretic 25.2  37.2  45.8  50.6  51.6  44.3  47.7  45.7
Thiazide  6.3  15.6  19.2  17.6  12.9  18.9  14.0  16.5
Potassium-sparing 10.0  11.2  10.4  10.2  8.7  10.9  9.6  10.3
Potassium-sparing  combination  8.3  9.8  9.2  8.9  7.5  9.5  8.3  8.9
Potassium  6.7  11.0  12.6  15.3  15.5  13.6  13.1  13.4
Calcium  channel  blocker  9.8  24.5  30.1  29.6  27.8  27.7  27.2  27.6
30  days  after  (%)  5.2  4.4  4.1  2.7  1.6  2.3  4.3  3.4
Beta-blockers  65.2  64.1  57.7  49.2  36.3  52.4  53.9  53.6
Speciﬁc  beta-blocker  46.0  38.6  32.9  27.6  20.6  28.5  33.2  31.2
ARB  13.1  21.5  24.3  21.3  15.3  23.7  18.6  21.1
ACEI  61.6  55.4  48.9  42.9  36.3  43.0  50.5  47.0
ACEI  or  ARB  72.5  74.6  71.4  63.1  51.0  65.0  67.7  66.6
Diuretics  (at  least  one)  75.5  82.8  86.4  86.8  85.1  85.0  85.6  85.2
Loop  diuretic  70.4  77.4  81.5  83.0  82.9  80.2  81.8  80.9
Thiazide  5.4  9.2  9.3  7.3  4.6  8.8  6.9  7.8
Potassium-sparing  30.3  24.7  18.4  14.1  9.4  16.7  17.9  17.5
Potassium-sparing  combination  27.7  23.1  17.3  13.3  9.0  15.8  16.7  16.4
Potassium  25.6  29.5  31.7  34.2  33.6  32.9  31.3  32.2
Calcium  channel  blocker  13.4  22.1  25.5  23.9  22.4  24.4  22.0  23.3
Pacemaker  (hospital  and  30  days)  0.7  1.3  2.3  2.5  1.6  1.7  2.5  2.0
ICD  (hospital  and  30  days)  4.5  3.1  1.7  0.2  0.0  0.6  1.8  1.3
Beta-blocker,  diuretic,  ACEI/ARB  combinations
6  months  before  (%)
ACEI/ARB  only  5.6  7.8  7.5  8.0  8.6  7.6  7.9  7.7
Beta-blocker  only  4.8  5.5  5.3  5.5  4.5  5.6  5.1  5.3
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Table  4  (Continued)
<  55  years  55—69  years  70—79  years  80—89  years  ≥  90  years  Womena Mena Total
Diuretic  only  30.9  19.4  11.0  3.7  11.6  11.4  10.2  10.7
ACEI/ARB  +  diuretic  8.1  15.4  21.6  23.9  22.5  20.7  21.2  20.8
ACEI/ARB  +  beta-blocker  6.8  8.1  7.2  5.1  3.3  5.2  6.6  6.1
Beta-blocker  +  diuretic  3.5  5.1  6.5  7.9  8.4  7.7  6.0  6.8
Beta-blocker  +  diuretic  +  ACEI/ARB  14.4  23.8  25.6  20.9  12.5  20.7  22.0  21.4
30  days  after  (%)
ACEI/ARB  only 2.9  2.9  2.5  2.6  3.0  2.7  2.7  2.7
Beta-blocker  only  3.1  2.6  2.2  1.8  1.7  2.3  2.0  2.1
Diuretic  only  8.7  8.6  11.0  16.3  25.6  14.7  13.8  14.1
ACEI/ARB  +  diuretic  13.4  18.8  23.8  25.7  26.6  23.6  23.7  23.4
ACEI/ARB  +  beta-blocker  8.8  6.1  3.9  2.6  1.6  3.5  3.9  3.8
Beta-blocker  +  diuretic  6.0  8.6  10.4  12.6  13.2  11.5  10.7  11.0
Beta-blocker  +  diuretic  +  ACEI/ARB  47.3  46.9  41.2  32.2  19.8  35.1  37.4  36.7
6  months  before  (%)
Cardiotonic  steroid  3.3  6.0  8.6  10.5  10.6  9.4  8.3  8.8
Class  III  antiarrhythmic  6.3  12.7  16.3  16.8  13.2  14.1  15.9  15.0
Nitrate  1.2  6.2  10.2  15.2  21.2  11.4  12.9  12.2
Oral  anticoagulant  13.0  23.1  29.7  28.4  15.9  24.5  27.0  25.7
Platelet  aggregation  inhibitor  21.4  38.8  43.7  43.0  44.8  35.9  46.7  41.4
Aspirin  18.0  30.0  33.0  32.6  35.5  28.1  35.0  31.7
Clopidogrel  9.0  16.5  17.5  15.1  11.3  11.8  18.6  15.2
Lipid-lowering  agents  23.2  46.3  50.8  38.4  17.4  36.0  44.1  40.0
Statins  21.2  41.9  44.8  32.7  14.7  30.3  39.8  35.0
Fibrates  1.6  3.6  5.4  5.3  2.7  5.4  3.7  4.6
Other  2.3  3.4  2.5  1.0  0.2  1.3  2.2  1.8
Antidiabetics  15.3  35.2  35.3  22.2  10.5  26.6  26.4  26.3
Insulin  7.2  14.9  13.5  7.9  3.5  11.6  9.0  10.1
Biguanide  7.9  19.0  16.5  7.0  2.3  10.9  11.5  11.1
Sulphonamides  4.7  12.7  13.6  8.9  4.5  9.5  10.8  10.1
Glinide  1.2  3.7  4.2  3.0  1.4  3.0  3.3  3.2
Thyroxin  5.0  8.3  11.2  12.1  11.5  16.0  5.6  10.7
Non-steroidal  anti-inﬂammatory  drug  5.8  7.7  8.1  7.7  5.2  9.4  5.7  7.5
Steroidal  anti-inﬂammatory  drug  6.2  5.7  5.8  5.1  4.3  5.5  5.3  5.3
Class  I  antiarrhythmic  1.2  2.7  3.8  3.7  2.6  4.0  2.6  3.3
30  days  after  (%)
Cardiotonic  steroid  8.1  10.3  11.5  13.5  14.2  13.7  10.4  12.2
Class  III  antiarrhythmic  15.0  24.2  27.0  24.7  20.0  23.2  24.8  24.2
Nitrate  5.1  11.0  15.2  18.5  25.3  15.1  17.3  16.3
Oral  anticoagulant  28.0  36.6  43.2  41.0  23.0  37.8  38.5  38.3
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Table  4  (Continued)
<  55  years 55—69  years 70—79  years 80—89  years ≥  90  years Womena Mena Total
Platelet  aggregation  inhibitor 37.1  50.9  48.9  45.3  49.8  41.5  52.5  47.2
Aspirin  33.8  43.8  40.8  36.9  41.7  35.1  43.2  39.4
Clopidogrel  14.5  21.9  20.7  16.7  12.0  14.4  21.4  18.0
Lipid-lowering  agents 33.1  54.2  52.9  37.8  16.3  37.1  47.0  42.1
Statins  31.8  51.3  49.4  34.8  15.0  33.9  44.5  39.3
Fibrates  0.8  2.3  2.9  2.7  1.2  2.8  2.0  2.4
Other  3.6  3.6  2.3  1.1  0.2  1.3  2.4  1.9
Antidiabetes  treatments  16.8  34.9  33.2  20.8  10.2  25.5  25.2  25.2
Insulin  8.6  16.4  14.9  9.8  5.3  13.3  10.5  11.7
Biguanide  6.8  14.5  11.1  4.2  1.1  7.4  7.9  7.6
Sulphonamides  5.2  11.7  10.6  6.7  3.3  7.6  8.7  8.2
Glinide  1.9  5.0  5.4  3.5  1.7  3.7  4.3  4.0
Thyroxin  6.2  8.8  11.4  12.1  11.3  15.9  6.1  10.9
Non-steroidal  anti-inﬂammatory  drug  4.5  5.0  4.0  3.2  2.5  4.5  3.1  3.7
Steroidal  anti-inﬂammatory  drug  7.3  6.8  6.8  6.2  6.0  6.8  6.3  6.5
Class  I  antiarrhythmic  1.2  1.5  1.5  1.3  0.8  1.8  1.0  1.4
In patients with at least one medicinal product reimbursement during these two periods. ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker.
a Age-standardized.
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In  addition,  the  use  of  potassium  supplements  increased
rom  13%  to  32%  after  hospitalization  and  the  use  of  class
II  antiarrhythmics  increased  from  15%  to  24%.  Increased
se  was  also  observed  for  oral  anticoagulants  (26%  to  38%)
nd,  to  a  lesser  degree,  platelet  aggregation  inhibitors  (41%
o  47%).  The  frequencies  of  use  of  antidiabetes  treatments
26%  to  25%)  and  lipid-lowering  drugs  (40%  to  42%)  remained
elatively  stable.  The  frequencies  of  use  of  non-steroidal
nd  steroidal  anti-inﬂammatory  drugs  were  7%  and  5%  before
ospitalization  and  4%  and  6%  after  hospitalization,  respec-
ively.
iscussion
his  study  demonstrated  a  high  incidence  of  ﬁrst  hospital-
zation  for  heart  failure,  especially  in  older  patients,  with  a
igher  incidence  in  the  northern  regions,  Corsica  and  Réu-
ion.  These  patients,  especially  the  youngest,  presented  a
igh  co-morbidity  rate  compared  with  the  other  beneﬁciar-
es.  The  hospital  mortality  rate  was  6%.  The  mortality  rate
uring  the  30  days  following  discharge  was  4%  and  the  all-
ause  readmission  rate  was  18%  (5%  for  HF)  for  patients  who
urvived  at  least  30  days.  The  frequency  of  the  beta-blocker,
iuretic  and  ACEI/ARB  combination  during  the  30  days  after
ischarge  was  37%  overall,  but  47%  in  the  55—69  years  age
roup.
pidemiology
any  epidemiological  studies  have  been  conducted  on  HF,
ut  with  various  objectives,  methodologies  and  sociodemo-
raphic  and  clinical  inclusion  criteria,  making  it  difﬁcult  to
ompare  their  results.  Higher  incidences  of  HF  have  been
eported  in  studies  including  all  hospitalized  patients  (ﬁrst
ospitalization  and  rehospitalizations).  In  2008,  in  France,
he  crude  hospitalization  rate  for  all  patients  was  0.23%,
egardless  of  age,  and  1.2%  for  patients  aged  ≥  65  years
vs.  0.14%  and  0.78%  in  our  study  on  ﬁrst  hospitalizations
or  HF)  [6].  In  1994,  a  hospitalization  rate  of  0.22%  was
eported  in  the  French  Lorraine  region  among  all  patients
ged  20—80  years  hospitalized  presenting  with  clinical  and
chocardiographic  criteria  of  advanced  HF  vs.  0.1%  in  this
tudy  for  the  same  age  group  [12].  In  Scotland,  in  2000,  a
hysician-based  survey  reported  an  outpatient  incidence  of
F  of  0.2%  among  patients  aged  ≥  45  years  and  5.0%  among
atients  aged  ≥  75  years  (vs.  1.2%  in  the  age  group  in  our
tudy)  [13].  The  ﬁrst  hospitalization  rate  for  HF  in  Scotland
n  2003  was  0.12%  in  men  and  0.1%  in  women,  close  to  the
ates  observed  in  our  study  [14].
The  regional  disparity  observed  in  the  present  study  can
e  explained  by  variations  in  the  distribution  of  risk  factors,
etiology,  diagnosis,  clinical  practice  and  indications  for  hos-
italization.  The  national  study  on  patients  hospitalized  for
F  in  2008  also  reported  higher  standardized  hospitaliza-
ion  rates  in  northern  regions  of  France  [6].  The  observed
eographical  distribution  is  similar  to  that  of  standard-
zed  regional  hospitalization  rates  for  myocardial  infarction
higher  in  the  northern,  north-eastern  and  south-eastern
egions)  and  stroke  (higher  in  the  northern  and  north-eastern
egions  and  in  Brittany)  [15].  In  2010,  the  regional  rates  of
reatment  for  hypertension  or  diabetes  were  also  higher  in
w
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he  northern  and  north-eastern  regions  and  in  French  over-
eas  departments  [16].
The  French  national  HF  hospitalization  study  reported  a
rowth  in  the  crude  hospitalization  rate  of  14.4%  between
002  and  2008,  while  the  age-standardized  rate  slightly
ecreased  (2.5%)  [6]. Nevertheless,  a  signiﬁcant  increase  in
he  hospitalization  rate  for  HF  was  observed  in  women  aged
5—54  years  and  in  the  hospitalization  rate  for  myocardial
nfarction  or  stroke  in  women  aged  <  55  years  [17,18].  Stud-
es  in  other  countries,  such  as  the  USA,  Canada  and  Scotland,
ave  also  reported  a  variable  reduction  in  standardized  hos-
italization  rates  for  HF  [19—22].  Among  hospitalizations  for
F,  a  growth  in  the  relative  proportion  of  systolic  HF  has  also
een  reported  in  the  USA  (33%  in  2005  and  39%  in  2010)  [22].
atient clinical characteristics
ccording  to  the  mode  of  patient  selection  in  this  study,
he  hospitalization  had  to  correspond  to  the  ﬁrst  episode
f  decompensation  in  patients  with  previously  known  or
nknown  HF.  However,  40%  of  the  patients  included  in  this
tudy  had  had  at  least  one  BNP  assay  during  the  previ-
us  year,  suggesting  screening  for  chronic  HF.  Furthermore,
lmost  20%  of  patients  were  already  being  treated  with
 beta-blocker,  diuretic  and  ACEI/ARB  triple  combination,
uggesting  that  the  diagnosis  of  HF  had  already  been  estab-
ished.
Data  in  the  literature  indicate  a  proportion  of  35—50%
f  diastolic  HF,  depending  on  the  study  and  the  age  of  the
atients  included,  and  this  proportion  increases  with  age
22,23].  The  two  forms  of  HF  cannot  be  distinguished  in  the
resent  study  due  to  the  lack  of  clinical  data.  The  relatively
igh  mean  age  of  patients  in  this  study  (77  years)  would
avour  a higher  proportion  of  diastolic  HF.  However,  analysis
f  the  ALD  status  for  chronic  diseases  revealed  a  relatively
igh  rate  of  diseases  responsible  for  systolic  HF,  such  as  coro-
ary  heart  disease  (15%),  diabetes  (20%),  arrhythmias  (4.9%)
nd  valvular  heart  disease  (3.7%),  but  also  severe  hyper-
ension  (16.3%).  Hospitalizations  for  coronary  heart  disease
r  cardiomyopathy  were  also  more  frequent  among  younger
atients,  who  were  more  frequently  hospitalized  in  univer-
ity  hospitals  and  in  intensive  care  units  due  to  differences
n  their  clinical  state  or  the  clinical  setting.
This  study  found  a  large  proportion  and  a  higher  fre-
uency  of  ALD  chronic  disease  status  for  tumours  of
aematopoietic  tissue  among  the  youngest  patients  hospi-
alized  for  HF.  Anthracyclines,  used  in  the  treatment  of
hese  tumours,  have  been  reported  to  induce  irreversible
nd  sometimes  late  deleterious  effects  on  cardiac  function
24]. Adjuvant  radiotherapy  used  in  the  1980s  for  the  treat-
ent  of  breast  cancers  and,  more  recently,  anthracyclines
nd  trastuzumab  have  also  been  associated  with  the  devel-
pment  of  HF  [25,26]. However,  these  hypotheses  could  not
e  conﬁrmed,  as  information  on  medicinal  products  in  the
NIIRAM  database  is  only  available  for  the  previous  3  years
lus  the  current  year.
A higher  frequency  of  reimbursement  for  antipsychotics
as  also  observed  among  the  youngest  patients  hospitalized
or  HF,  which  may  reﬂect  risk  behaviour,  and  a  higher  rate  of
ardiovascular  risk  factors,  which  can  also  be  related  to  the
se  of  antipsychotics,  as  some  of  them  have  been  reported
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to  be  associated  with  hypotension,  diabetes,  arrhythmias,
cardiomyopathies  and  sudden  death  [27].
Treatment and management
Recent  European  guidelines  concerning  the  treatment  of  sys-
tolic  HF  recommend  ﬁrst-line  prescription  of  an  ACEI,  or
an  ARB  when  the  ACEI  is  not  well  tolerated,  followed  by
introduction  of  a  beta-blocker.  When  the  New  York  Heart
Association  score  is  still  III  or  IV,  it  is  recommended  to  add
an  aldosterone  antagonist.  If  no  improvement  in  left  ven-
tricular  ejection  fraction  (<  35%)  is  observed,  ivabradine  can
be  used  and,  if  still  no  improvement  is  obtained,  place-
ment  of  a  cardiac  resynchronization  device  and  the  use
of  digoxin.  Diuretics  are  recommended  to  decrease  symp-
toms  or  signs  of  congestion.  No  speciﬁc  guidelines  have
been  proposed  for  diastolic  HF  apart  from  symptomatic
treatment  and  treatment  of  the  underlying  cardiovascular
disease  [10].  The  French  FUTURE  study  (2007—2008)  failed
to  demonstrate  any  signiﬁcant  differences  in  treatment
frequencies  on  hospital  discharge  and  at  outpatient  visits
between  patients  with  a  left  ventricular  ejection  fraction
>  40%  (44%  of  patients)  or  <  40%  (56%  of  patients)  [23].  Among
the  1137  patients  (mean  age  72  years)  followed  by  an  ofﬁce
cardiologist,  83%  were  treated  with  an  ACEI/ARB,  74%  with
beta-blockers,  31%  with  an  aldosterone  antagonist  and  86%
with  a  loop  diuretic.  The  French  IMPACT  RECO  study,  in  2005,
comprising  2000  patients  (mean  age  70  years)  with  New  York
Heart  Association  grade  III  and  IV  systolic  HF  followed  by
ofﬁce  cardiologists,  reported  fairly  similar  treatment  fre-
quencies:  68%  for  ACEIs  and  30%  for  ARBs  (i.e.  91%  for  an
ACEI/ARB,  70%  for  beta-blockers  [the  highest  increase],  35%
for  aldosterone  antagonists  and  85%  for  loop  diuretics)  [28].
The  EuroHeart  Failure  Survey  II  in  2004—2005  reported  that
71%  patients  (mean  age  70  years)  were  treated  with  an  ACEI
and  80%  with  an  ACEI/ARB,  61%  of  patients  were  treated
with  a  beta-blocker  on  discharge  from  hospital,  41%  with  an
aldosterone  antagonist  and  90%  with  a  diuretic  [29].  In  the
present  study,  the  frequencies  of  drug  treatments  30  days
after  hospitalization  were  much  lower  than  those  reported
above  (beta-blocker  54%,  ACEI  47%,  ACEI/ARB  67%,  diuretic
85%,  aldosterone  antagonist  33%).  However,  patients  in  our
study  were  older  (mean  age  77  years)  and  probably  more
frequently  presented  contraindications  to  the  use  of  drugs
such  as  ACEIs  and  beta-blockers.  This  is  illustrated  by  higher
prescriptions  of  beta-blockers  in  more  than  60%  of  cases  and
ACEIs/ARBs  in  about  75%  of  cases  in  patients  aged  <  80  years.
Some  treatments,  such  as  beta-blockers,  may  also  have  been
introduced  subsequently,  after  the  ﬁrst  month.
About  30%  of  patients  attended  a  visit  with  a  cardiologist
or  were  assessed  by  echocardiography  at  the  ﬁrst  month
after  hospitalization,  with  higher  rates  for  the  youngest
patients,  and  at  least  one  BNP  assay  was  performed  in  16%  of
cases.  French  guidelines  for  the  management  of  systolic  HF
after  hospitalization  recommend  at  least  a  follow-up  visit
by  a  cardiologist  to  adapt  treatment  according  to  the  New
York  Heart  Association  stage,  BNP  assay  in  the  presence  of  a
suspicion  of  decompensation  and  echocardiography  in  the
presence  of  symptoms  or  deterioration  [10].  Early  medi-
cal  management  after  discharge  from  hospital  and  regular
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ollow-up  by  a  cardiologist  have  been  identiﬁed  as  factors
ssociated  with  a  lower  readmission  rate  [30,31].
ortality and readmission
here  is  an  ongoing  debate  concerning  the  impact  of  early
ischarge  from  hospital,  as  the  reduction  in  mean  length
f  hospital  stay  could  result  in  higher  early  mortality  and
0-day  readmission  rates  [7]. In  2008,  the  mean  length  of
ospital  stay  for  HF  in  France  was  9.9  days,  higher  than  the
ean  stay  of  9.2  days  in  our  study,  which  was  limited  to
rst  hospitalizations  [6].  For  comparison,  the  mean  length
f  hospital  stay  for  all  patients  with  HF  is  shorter  in  the  USA
han  in  France  (8.8  days  in  1993  and  6.3  days  in  2006)  and  is
ending  to  decline  [20].
The  hospital  mortality  rate  was  6.4%  in  our  study  vs.  7.5%
n  the  study  on  all  hospitalizations  for  HF  in  France  in  2008
6]. A  similar  hospital  mortality  rate  of  6.7%  was  observed  in
he  European  EuroHeart  Survey  II,  comprising  a  younger  sur-
ey  population  (mean  age  70  years  vs.  77  years  in  our  study)
ith  a  median  length  of  stay  of  9  days  [31].  In  the  USA,  the
ospital  mortality  rate  decreased  from  8.5%  in  1993  to  4.3%
n  2006  among  Medicare  beneﬁciaries  [32].  However,  the  30-
ay  post-hospital  mortality  rate,  although  it  also  decreased
rom  17%  to  13%,  was  higher  than  that  reported  in  our  study
11%),  which  was  limited  to  incident  cases  of  hospitaliza-
ion.  Thirty-day  all-cause  and  HF  readmission  rates  in  our
tudy  were  18%  and  5.1%,  respectively.  The  2008  national
tudy  reported  a  20%  readmission  rate  for  HF  during  the  ﬁrst
ear  and  75%  of  these  readmissions  occurred  during  the  ﬁrst
 months  after  discharge  [6].  Similar  30-day  all-cause  and  HF
eadmission  rates  of  22%  and  6.1%  were  reported  in  veterans
overed  by  Medicare  in  2008  in  the  USA  [7].
trengths and limitations
n  the  basis  of  available  data,  this  study  tried  to  iden-
ify  and  give  the  characteristics  of  the  ﬁrst  hospitalizations
or  HF  in  France.  The  possibility  of  ﬁrst  hospitalizations
efore  2006  (i.e.  >  3  years  before  the  inclusion  period  of
his  study)  cannot  be  eliminated.  One-year  and  5-year  mor-
ality  rates  of  20—30%  and  45—60%,  respectively,  have  been
eported  [1].  The  bias  is  therefore  limited.  Certain  groups  of
he  French  population  were  not  included  in  this  study  due
o  their  occupation,  such  as  civil  servants,  liberal  profes-
ionals  and  farmers,  as  they  are  covered  by  other  health
nsurance  schemes.  These  groups  may  differ  in  terms  of
heir  age  structure  and  other  sociodemographic  character-
stics,  their  exposures  and  their  management  and  access  to
ealthcare.  Institutionalized  subjects  (e.g.  in  an  Établisse-
ent  d’Hébergement  pour  Personnes  Âgées  Dépendantes
EHPAD;  accommodation  facility  for  dependent  elderly])
ere  not  included  in  this  analysis,  especially  concerning
heir  individual  medicinal  product  consumption,  which  is
ncluded  in  the  accommodation  costs.  The  data  used  in
his  study  were  derived  from  medical  and  administrative
atabases  that  collect  only  limited  clinical  information,
uch  as  those  necessary  for  the  distinction  between  sys-
olic  and  diastolic  HF,  which  is  one  of  the  major  limitations
f  this  study.  These  databases  also  have  the  classical  lim-
tations  concerning  the  validity  of  data  collection  and
ata  coding,  such  as  coding  of  diagnoses  and  chronic
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[84  
isease.  Estimation  of  chronic  disease  status  using  ALD  could
e  underestimated  because  the  100%  reimbursement  of
ealthcare  expenditure  is  not  useful  for  institutionalized
eople,  those  with  mutual  insurance  or  those  with  a  pre-
xisting  ALD.  Some  frequencies  could  be  underestimated,
specially  for  laboratory  assays  performed  in  public  hospi-
als,  or  reimbursement  of  certain  medicinal  products  when
hey  are  dispensed  during  a  stay  in  an  institution.
onclusion
his  study  revealed  a  high  incidence  of  ﬁrst  hospitalization
or  HF,  especially  among  very  elderly  patients  presenting
igh  rates  of  co-morbidity.  The  study  also  demonstrated
 high  mortality  rate  and  a  high  early  readmission  rate.
inally,  despite  the  limitations  of  the  databases  used  for
his  study,  there  still  appears  to  be  room  for  improvement
n  the  drug  treatment  prescribed  on  discharge,  in  terms  of
requency  and  combination  therapies,  in  order  to  lower  the
eadmission  rate.  As  mentioned  in  the  introduction,  disease
anagement  programmes  have  been  demonstrated  to  be
ffective  in  many  trials,  in  terms  of  readmission  rates  and
uality  of  life,  and  are  therefore  now  included  in  clinical
ractice  guidelines.  The  French  national  health  insurance
und  (CNAMTS)  is  currently  developing  a  return-home  and
ollow-up  management  programme  (PRADO)  for  patients
ospitalized  for  HF  in  partnership  with  general  practitioners.
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